SC
NGNE icon

Steven Cohen’s Neurogene NGNE Stock Holding History

Steven Cohen’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200,000
Closed -$2.34M – 2471
2025
Q1 		$2.34M Buy
+200,000
New +$3.47M 0.01% 1197

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Steven Cohen's NGNE Position: Q2 2026 in Review

Steven Cohen opened a new position in Neurogene (NGNE) in Q2 2026: 141,920 shares worth $4.46M. The stake represents ﹤0.01% of the portfolio and ranks #1836 among its holdings. This is a return to the name: Steven Cohen previously reported a position in NGNE as recently as Q3 2025.

Steven Cohen first reported a position in NGNE in Q4 2017 and has held it in 21 quarters since. The position peaked at $16.9M in Q4 2020. 111 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Steven Cohen held 141,920 shares of Neurogene worth $4.46M as of Q2 2026.
  • Neurogene was a new Steven Cohen position in Q2 2026.
  • Neurogene made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #1836 holding.
  • Steven Cohen first reported a position in Neurogene in Q4 2017 and has held it in 21 quarters since.
  • Steven Cohen's Neurogene position peaked at $16.9M in Q4 2020.
  • 111 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.